Impact of Sacubitril/Valsartan on Clinical and Echocardiographic Parameters in Heart Failure Patients With Reduced Ejection Fraction: Data From a Real Life 2-year Follow-Up Study
Heart failure (HF) represents a widespread health problem characterized by high morbidity and mortality. Sacubitril/Valsartan (sac/val) has improved clinical prognosis in patients affected by HF with reduced ejection fraction (HFrEF). The aim of this study was to evaluate the effectiveness and durab...
Main Authors: | Giuseppe Armentaro, Graziella D’Arrigo, Marcello Magurno, Alfredo F. Toscani, Valentino Condoleo, Sofia Miceli, Velia Cassano, Raffaele Maio, Franco Arturi, Giovanni Tripepi, Giorgio Sesti, Angela Sciacqua |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-08-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.733475/full |
Similar Items
-
Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis
by: Sha Fu, et al.
Published: (2021-06-01) -
Sacubitril/valsartan improves cardiac function in Chinese patients with heart failure: a real‐world study
by: Wenwen Chen, et al.
Published: (2021-10-01) -
Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
by: David Carballo, et al.
Published: (2020-06-01) -
Sacubitril/valsartan decreases mortality in the rat model of the isoprenaline‐induced takotsubo‐like syndrome
by: Anwar Ali, et al.
Published: (2021-10-01) -
Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty
by: Francesco Cacciatore, et al.
Published: (2020-04-01)